|
Keli Hippen, Ph.D.
 Keli Hippen, Ph.D. Division of Pediatric Hematology-Oncology and Blood and Marrow Transplantation Assistant Professor Mayo Mail Code 366 420 Delaware St. SE Minneapolis, MN 55455 Phone: (612) 625-1430 Fax: (612) 624-3913 hippe002@umn.edu Preferred method of contact: Phone Dr. Hippen is an Assistant Professor in the Department of Pediatrics, Division of Hematology-Oncology and Blood and Marrow Transplantation. He is a member of the Cancer Center and the supervisor for the Human Immunotherapy Lab. Dr. Hippen was a faculty member here at the University of Minnesota in the Department of Medicine, Division of Rheumatology from 2001 until joining the Department of Pediatrics in August 2006. Dr. Hippen received his Ph.D. degree from Iowa State University in 1993, followed by post-doctoral positions at the National Jewish Medical and Research Center (1993-1996) and the University of Minnesota (1996-1999). He remained at the University of Minnesota, becoming a Research Assistant (1999-2001) and joining the faculty as noted above in 2001. Dr. Hippen has had papers published in journals such as Science, Immunity, and the Journal of Experimental Medicine. Research Interests Dr. Hippen’s research is focused on inhibiting Graft Versus Host Disease (GVHD), which is a frequent and severe complicating factor in bone marrow transplants. GVHD is a T cell mediated disease, that arises in autoimmune fashion due to graft-derived immune cells recognizing recipient cells as non-self. Activation of autorective T cells (and those that induce GVHD) is normally prevented by a subset of T cells termed regulatory T cells (Treg). Transplant of donor Treg has been shown to ameliorate disease in mouse models of both GVHD and autoimmunity. Dr. Hippen’s specific interest is defining the mechanisms that control human regulatory T cell proliferation and function with the goal of generating large numbers of very active cells that can be co-transferred at the time of bone marrow transplantation and reduce or completely abolish GVHD. In collaboration with Dr. Jakub Tolar, he is also exploring gene transfer studies to create more effective Treg cells based on antigen specificity and/or longevity. Selected Recent Publications: Hippen, K.L., Merkel, S.C., Schirm, D.K., Sieben, C.M., Sumstad, D., Kadidlo, D.M., McKenna, D.H., Bromberg, J.S., Levine, B.L., Riley, J.L., et al. 2011. Massive ex vivo expansion of human natural regulatory T cells (Tregs) with minimal loss of in vivo functional activity. Science Translational Medicine 3:78ra33. http://stm.sciencemag.org/cgi/rapidpdf/3/83/83ra41?ijkey=ub.Apr.hqxXn6&keytype=ref&siteid=scitransmed Hippen, K.L., Merkel, S.C., Schirm, D.K., Nelson, C., Tennis, N.C., Riley, J.L., June, C.H., Miller, J.S., Wagner, J.E., and Blazar, B.R. 2011. Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease. Am J Transplant. May 12. doi: 10.1111/j.1600-6143.2011.03558.x. Zanin-Zhorov A, Ding Y, Kumari S, Attur M, Hippen K.L., Brown M., Blazar B.R., Abramson S.B., Lafaille J.J., Dustin M.L. (2010) Protein Kinase C-{theta} Mediates Negative Feedback on Regulatory T Cell Function. Science 328 (5976): 372-376. Brunstein, C.G., Miller, J.S., Cao, Q., McKenna, D.H., Hippen, K.L., Curtsinger, J., DeFor, T., Levine, B.L., June, C.H., Rubinstein, P., McGlave, P.B., Blazar, B.R., and Wagner, J.E. (2010) Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics Blood 2010 : blood-2010-07-293795v1-blood-2010-07-293795. Tolar, J., Hippen, K.L., Blazar, B.R. (2009) Immune regulatory cells in umbilical cord blood: T regulatory cells and mesenchymal stromal cells. Br J Haematol. 147(2):200-206. Hippen, K.L., Harker-Murray, P., Porter, S.B., Merkel, S.C., Londer, A., Taylor, D.K., Bina, M., Panoskaltsis-Mortari, A., Rubinstein, P., Van Rooijen, N., et al. 2008. Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. Blood 112:2847-2857. Will, W.M., Aaker, J.D., Burchill, M.A., Harmon, I.R., O'Neil, J.J., Goetz, C.A., Hippen, K.L., Farrar, M.A. (2006) Attenuation of IL-7 receptor signaling is not required for allelic exclusion. J Immunol. 176:3350-3355. Liu, J., Karypis, G., Hippen, K.L., Vegoe, A.L., Ruiz, P., Gilkeson, G.S., & Behrens, T.W. (2006). Genomic view of systemic autoimmunity in MRLlpr mice. Genes and Immunity 7, 156–168. Hippen, K.L., Schram, B.R., Pape, K.A., Jenkins, M.K., & Behrens, T.W. (2004). Efficient Light Chain Receptor Editing of Self-Reactive B Cells in Response to Membrane antigens. Accepted pending minor revisions, J. Immunol., 2005 Tze, L.E., Schram, B.S., Hogquist, K.A., Hippen, K.L., Liu, J., Shinton, S.A., Rodine, P.R., Vegoe, A.L., Hardy, R.R., Schlissel, M., Rajewsky, K. & Behrens, T.W. (2005) Basal Immunoglobulin Signaling Actively Maintains Light Chain Allelic Exclusion and Developmental Stage in Immature B Cells. PLoS Biol. 3(3):e82. Swanson, P.J., Kuslak, S.L., Fang, W., Tze, L., Gaffney, P., Selby, S., Hippen, K.L., Nunez, G., Sidman, C.L., & Behrens, T.W. (2004). Fatal Acute Lymphoblastic Leukemia in Mice Transgenic for B Cell-Restricted bcl-xL and c-myc. J. Immunol. 172: 6684-6691. Tze, L.T., Hippen, K.L., & Behrens, T.W. (2003). Late Immature B Cells (IgMhighIgDneg) Undergo a Light Chain Receptor Editing Response to Soluble Self-Antigen. J. Immunol. 171: 678-682. Pape, K.A., Kouskoff, V., Nemazee, D., Tang, H.L., Cyster, J.G., Tze, L.E., Hippen, K.L., Behrens, T.W., & Jenkins, M.K. (2003). Visualization of the Genesis and Fate of Isotype-switched B Cells during a Primary Immune Response. J. Exp. Med 197: 1677-1687. Tze, L.T., Baness, E.A., Hippen, K.L., & Behrens, T.W. (2000). Immunoglobulin Light Chain Receptor Editing in Anergic B Cells. J. Immunol. 165: 6796-6802. Hippen, K.L., Tze, L., & Behrens, T.W. (2000). CD5 Maintains Tolerance in Anergic B Cells. J. Exp. Med 191: 883-890. Hippen, K.L., Buhl, A.M., D'Ambrosio, D., Nakamura, K., Persin, C., & Cambier, J.C. (1996). FcgRIIB1 Inhibition of BCR-Mediated Phosphoinositide Hydrolysis and Ca2+ Mobilization Is Integrated by CD19 Dephosphorylation. Immunity 7: 49-58. D'Ambrosio, D.*, Hippen, K.L., Minskoff, S.A., Mellman, I., Pani, G., Siminovitch, K.A., & Cambier, J.C. (1995). Recruitment and Activation of PTP-1C in Negative Regulation of Antigen Receptor Signaling by FcgRIIB1. Science 268: 293-297.
|